RC
MYGN icon

RegentAtlantic Capital’s Myriad Genetics MYGN Stock Holding History

RegentAtlantic Capital’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-390
Closed -$13.3K – 702
2014
Q4 		$13.3K Buy
+390
New +$13.8K ﹤0.01% 843

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

RegentAtlantic Capital's MYGN Position: Q1 2015 in Review

RegentAtlantic Capital sold out of Myriad Genetics (MYGN) in Q1 2015, closing a stake of 390 shares — an estimated $13.3K sold.

RegentAtlantic Capital first reported a position in MYGN in Q4 2014 and held it in 1 quarter. The position peaked at $13.3K in Q4 2014. 251 funds tracked by Wall St. Rank hold MYGN as of Q1 2015.

  • RegentAtlantic Capital reported no remaining Myriad Genetics position as of Q1 2015 after selling out during the quarter.
  • RegentAtlantic Capital sold 390 Myriad Genetics shares in Q1 2015, an estimated $13.3K.
  • RegentAtlantic Capital first reported a position in Myriad Genetics in Q4 2014 and held it in 1 quarter.
  • RegentAtlantic Capital's Myriad Genetics position peaked at $13.3K in Q4 2014.
  • 251 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2015.

Based on RegentAtlantic Capital's 13F filing for Q1 2015, filed 27 Apr 2015.